Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials
Blette B, Moutchia J, Al-Naamani N, Ventetuolo C, Cheng C, Appleby D, Urbanowicz R, Fritz J, Mazurek J, Li F, Kawut S, Harhay M. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials. The Lancet Respiratory Medicine 2023, 11: 873-882. PMID: 37230098, PMCID: PMC10592525, DOI: 10.1016/s2213-2600(23)00155-8.Peer-Reviewed Original ResearchMeSH KeywordsEpoprostenolFamilial Primary Pulmonary HypertensionFemaleHumansMaleMiddle AgedPulmonary Arterial HypertensionRandomized Controlled Trials as TopicRisk FactorsConceptsPulmonary arterial hypertensionPulmonary arterial hypertension trialsWorsening pulmonary arterial hypertensionFood and Drug AdministrationLow-risk statusClinical worseningLong-term outcomesRisk scoreArterial hypertensionPAH associated with connective tissue diseaseIdiopathic pulmonary arterial hypertensionPulmonary arterial hypertension treatmentSurrogate outcomesObservational study of outcomesLong-term follow-upDiscontinuation of study treatmentWHO functional classUS Food and Drug AdministrationMeta-analysisMeta-analysis of RCTsAll-cause deathConnective tissue diseaseEffects of therapyPredictive of outcomeTreatment effects